AMIODARONE OMEGA SOLUTION

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

AMIODARONE HYDROCHLORIDE

MAH:

OMEGA LABORATORIES LIMITED

ATC_code:

C01BD01

INN:

AMIODARONE

dosage:

50MG

pharmaceutical_form:

SOLUTION

composition:

AMIODARONE HYDROCHLORIDE 50MG

administration_route:

INTRAVENOUS

units_in_package:

100

prescription_type:

Prescription

therapeutic_area:

CLASS III ANTIARRYTHMICS

leaflet_short:

Active ingredient group (AIG) number: 0118593002; AHFS:

authorization_status:

APPROVED

authorization_date:

2004-04-05

SPC

_Amiodarone Omega _
_Page 1 of 59 _
PRODUCT MONOGRAPH PR
AMIODARONE OMEGA
Amiodarone hydrochloride for injection
House Standard
Vials: 50 mg/mL
Antiarrhythmic Agent
Omega Laboratories Limited.
Date of Revision: June 4, 2018
11 177 Hamon
Montreal, Quebec
H3M 3E4
Control Number: 213232
_Amiodarone Omega _
_Page 2 of 59 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
15
DRUG INTERACTIONS
.......................................................................................................................
18
DOSAGE AND ADMINISTRATION
...................................................................................................
22
OVERDOSAGE
.....................................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
27
STORAGE AND STABILITY
...............................................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
.............................................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................... 30
PART II: SCIENT